Transforming growth factor beta (TGF-β) is the main cytokine responsible for the induction of the epithelial-mesenchymal transition of breast cancer cells, which is a hallmark of tumor transformation to the metastatic phenotype. Recently, research demonstrated that the chemokine CCL2 gene expression level directly correlates with the TGF-β activity in breast cancer patients. CCL2 attracts tumor-associated macrophages and is, therefore, considered as an important inductor of breast cancer progression; however, the precise mechanisms underlying its regulation by TGF-β are unknown. Here, we studied the behavior of the CCL2 gene in MDA-MB-231 and HCC1937 breast cancer cells representing mesenchymal-like phenotype activated by TGF-β. Using bioinformatics, deletion screening and point mutagenesis, we identified binding sites in the CCL2 promoter and candidate transcription factors responsible for its regulation by TGF-β. Among these factors, only the knock-down of EGR1 and RXRA made CCL2 promoter activity independent of TGF-β. These factors also demonstrated binding to the CCL2 promoter in a TGF-β-dependent manner in a chromatin immunoprecipitation assay, and point mutations in the EGR1 and RXRA binding sites totally abolished the effect of TGF-β. Our results highlight the key role of EGR1 and RXRA transcription factors in the regulation of CCL2 gene in response to TGF-β pathway.
Transforming growth factor beta (TGF-β) is a cytokine that acts as a tumor suppressor in normal conditions and in the early stages of breast cancer (BC) development1. BC progression leads to the modification of TGF-β-dependent signaling pathways, which results in the altered response of a cancer cells to TGF-β, the elevated production of TGF-β, and modification of the tumor microenvironment2. In particular, enhanced TGF-β production is associated with the differentiation of myeloid-derived suppressor cells and regulatory T-helpers, which provoke tumor development by the inhibition of local inflammatory processes3. One of the key pathogenic functions of TGF-β is the induction of the epithelial-mesenchymal transition that results in the loss of the epithelial phenotype of the tumor and its transition to the aggressive metastatic stage4. This process is accompanied by activation of the range of genes responsible for the invasion and migration of cancer cells. A series of studies demonstrated that TGF-β was able to activate the expression of chemokines that enhance the metastatic potential of tumor cells5. Specifically, TGF-β induced the expression levels of CXCL1—attracts myeloid cells in the primary tumor site6, CXCL5—attracts neutrophils7, and CCL20—stimulates proliferative and migrative activity of BC cells8.
However, until recently, there was no information regarding the effect of TGF-β on CCL2 chemokine expression in BC cells, and the association of increased TGF-β/Smad3 expression with CCL2 induction in smooth muscle cells is poorly translated to cancer cells9. CCL2 (classically named MCP-1, monocyte chemoattractant protein 1), is known to be a powerful monocyte chemoattractant and to strongly induce metastasis formation by BC cells. In particular, lung metastases are associated with the involvement of inflammatory monocytes expressing the CCR2 receptor, which differentiate into metastasis-associated macrophages that prepare the microenvironment for cancer cells extravasation, as well as stimulate tumor growth at the site of metastasis10. CCL2 has also been shown to play a key role in attracting tumor-associated macrophages (TAM) to the primary tumor site11. TAM contributes to tumor progression by inducing angiogenesis, intensifying the epithelial–mesenchymal transition, and stimulating the intravasation of cancer cells12. In general, the elevated expression of CCL2 by BC cells is associated with an aggressively metastasizing tumor phenotype and with poor prognoses in patients13.
Recent studies demonstrated that the CCL2 gene expression level directly correlates with the TGF-β activity in breast cancer patients. These data are supported by the fact that, in the 4T1-BALB/c BC allograft mouse model, the inhibition of TGF-β causes a significant reduction in the levels of CCL2 expression in the primary tumor site, which correlates with lower levels of lung metastases14. In addition, it has been reported that TGF-β effects on CCL2 expression strongly depend on BC cell phenotype and activation is typical for advanced-stage BC cells14. In the current study, we aimed to identify the mechanism underlying regulation of CCL2 gene expression by TGF-β in advanced-stage triple-negative BC cells with mesenchymal-like phenotype.
Characterization of potential CCL2 promoter region
The CCL2 promoter region was not described and characterized earlier; therefore, we performed its identification using the following epigenetic data represented in the UCSC Genome Browser (http://genome.ucsc.edu/, Human Feb. 2009 GRCh37/hg19 Assembly) as described earlier15: DNase-I hypersensitivity clusters, histone modifications (H3K4me3, H3K4me1, and H3K27ac), the localization of transcription factor (TF) binding sites, and information on chromatin segmentation that combines data on different epigenetic parameters16. Based on these data, we identified the region spanning from − 1196 to + 488 bp from the CCL2 transcription start site (TSS) as the potential promoter (Fig. 1).
TGF-β1 induces CCL2 gene expression and CCL2 promoter activity in advanced stage triple-negative breast cancer cell lines
In the current study, we used MDA-MB-231 and HCC1937 triple negative human breast cancer cell lines that are reported to overexpress CCL217 and demonstrate mesenchymal-like phenotype18,19. We verified that TGF-β could induce CCL2 expression in triple-negative breast cancer cells with mesenchymal-like phenotype as it was indicated in previously published data14. The incubation of MDA-MB-231 and HCC1937 cells with 10 ng/mL of recombinant TGF-β1 protein (ab50036, Abcam, Cambridge, UK) for 24 h led to significant induction of expression levels of the IL-11 and CXCR4 genes (Fig. 2A), which are considered as the main TGF-β-induced targets1. The incubation of MDA-MB-231 cells with TGF-β1 resulted in higher levels of the phospho-SMAD3 (Ser 204) and phospho-SMAD2 (Ser465/467) forms, the key participants of canonical TGF-β intracellular cascade20. All of these TGF-β-dependent effects correlated with the stimulation of both CCL2 mRNA (Fig. 2A) and protein (Fig. 2B) levels that indicated the response of CCL2 on TGF-β stimulation.
In addition, incubation of MDA-MB-231 and HCC1937 breast cancer cells with TGF-β1 (10 ng/mL, for 24 h) led to a 1.5–twofold increase in the level of CCL2 promoter activity in the luciferase reporter system (Fig. 2C). These results highly correlate with the expression data and confirm the role of TGF-β signaling in the regulation of the CCL2 promoter.
To perform a more comprehensive analysis of SMAD proteins in TGF-β1-dependent regulation of CCL2 promoter we measured the levels of several other SMAD family members, SMAD4, SMAD6 and SMAD7 (Fig. 2B). SMAD4 is known to form a complex with activated p-SMAD2/3 which acts as a direct transcriptional activator of TGF-β-dependent target genes21,22. We detected no change in SMAD4 protein expression in response to TGF-β1 while the levels of p-SMAD2 and p-SMAD3 were induced. Apparently, SMAD4 activation is not required for the complex formation because the protein is already present in the cytoplasm and is recruited to the complex in a non-phosphorylated form21. Efficient complex formation is supported by the induction of IL11 and CXCR4 that have been reported to be direct p-SMAD2/3-SMAD4 target genes23. SMAD6 and SMAD7 have been shown to reduce the activity of p-SMAD2/3-SMAD4 complex acting in an antagonistic way22 and are therefore considered as inhibitory members of the SMAD family. The unchanged SMAD6 and SMAD7 proteins levels support the activating nature of intracellular TGF-β receptor signaling in MDA-MB-231 cells.
In order to check whether p-SMAD2/3-SMAD4 complex is able directly activate the CCL2 gene, we tested CCL2 promoter activity in TGF-β-induced MDA-MB-231 cells in the presence of specific siRNAs against SMAD2, SMAD3 and SMAD4 (Fig. 4D,E). Only SMAD3 knockdown significantly abrogated CCL2 promoter activation after TGF-β treatment indicating that other proteins of SMAD family do not interact directly with the promoter.
− 244/− 1 region of the CCL2 promoter is responsible for its TGF-β-dependent regulation
We applied deletion screening of CCL2 promoter to identify its region responsible for TGF-β1-dependent activation. The activities of luciferase reporter constructs containing deletion variants of the CCL2 promoter were assessed in MDA-MB-231 breast cancer cells in the presence or absence of TGF-β1 (10 ng/mL, 24 h), (Fig. 3). All promoter regions except Prom 6 demonstrated the dependence on TGF-β-induced activation. In the case of Prom 6, this effect was completely absent, although this region is essential for maintaining basal promoter activity. Comparing the character of influence of TGF-β1 on the activities of Prom 5 and Prom 6, the region is likely located within positions − 244 and − 1 in response to CCL2 transcription start site should be responsible for the dependence of CCL2 promoter on TGF-β.
EGR1 and RXRA transcription factors are essential for TGF-β-dependent activation of the CCL2 promoter
To identify potential transcription factors binding sites within the − 244/− 1 region of the CCL2 promoter we used the MoLoTool (http://molotool.autosome.ru) online service, which allows the search for transcription factor binding sites in a given sequence using curated models of these sites presented in the HOCOMOCO database (http://hocomoco11.autosome.ru/)24. For the first step, we formed a list of transcription factors with “strong” (− log10(P-value) > 5) predicted sites within the 244/− 1 region: MAZ, SP4, EGR2, THAP1, VEZF1, PAX6, SP1, RXRA, WT1, SP3, ZN768, BCL6, ZSC22, SP2, KLF3, RARA, ZBT14, and EGR1. In the next step, based on published data, we selected those factors from the list that are known to be involved in TGF-β-induced cascades: EGR125, EGR226, PAX627, RARA and RXRA28, and SP129. All selected transcription factors demonstrated high expression levels in both MDA-MB-231 and HCC1937 cell lines according to the mRNA expression data represented in the Broad Institute Cancer Cell Line Encyclopedia (Supplementary Table S2), which was used as an additional selection criterion.
To reveal the roles of these factors in CCL2 promoter regulation, we estimated the activity of the full-size CCL2 promoter (Prom 1) and its Prom 5 and Prom 6 fragments in MDA-MB-231 cells in normal conditions and in the presence of TGF-β1 (10 ng/mL, 24 h) or/and specific siRNAs against EGR1, EGR2, PAX6, RARA, RXRA, and SP1 factors mRNAs. The efficiency of siRNAs in suppressing the expression of these factors was preliminarily estimated by qPCR in the MDA-MB-231 cell line and was not less than 80% (Fig. 4A). TGF-β1 induced expression of all of the studied transcription factors except for EGR1 and SP130,31. siRNA knock-downs of all the factors abolished the activation of the corresponding genes and in the absence of TGF-β1 had no effects on the activity of CCL2 promoter variants (Fig. 4B, top panel). The Prom 6 fragment demonstrated no dependence on both TGF-β1 activation and the levels of any of the studied factors (Fig. 4B, bottom panel). The knock-down of any of EGR1 or RXRA completely abolished the effect of Prom1 and Prom 5 stimulation in response to TGF-β1. According to these results, EGR1 and RXRA could be considered as the main mediators of TGF-β1-dependent regulation of the CCL2 promoter.
Transfection of MDA-MB-231 cells with EGR1- or RXRA-specific siRNAs led to reduced levels of the respective proteins in the nucleus (Fig. 4C) and these levels could not be induced by TGF-β1 (10 ng/mL, 24 h). In the absence of specific siRNAs, TGF-β1 treatment resulted in elevated RXRA protein levels in the nucleus and did not influence EGR1 protein level, in agreement with mRNA expression data (Fig. 4A). At the level of the CCL2 mRNA, either EGR1- or RXRA-specific siRNA abrogated the TGF-β1-triggered effect almost as completely as both siRNAs together, both in MDA-MB-231 and in HCC1937 cells (Fig. 4D).
Both EGR1 and RXRA bind to the CCL2 promoter after TGF-β treatment independently in a time-dependent manner
To estimate the influence of TGF-β on the efficiency of EGR1 and RXRA binding to the CCL2 promoter in vivo, we used a classical chromatin immunoprecipitation (ChIP) assay. As the EGR1- and RXRA-binding sites are located in the same (− 244/− 1) region of the promoter, we analyzed the amount of cross-linked DNA from MDA-MB-231 and HCC1937 cells precipitated with anti-EGR1 and anti-RXRA antibodies using the primers corresponding to this region (schematically illustrated in Fig. 5A). We performed ChIP analysis for both cell lines activated by TGF-β1 (10 ng/mL) for 1, 2, 6 and 12 h. In order to determine whether RXRA and EGR1 could cooperatively bind to the same region of the promoter we also performed co-immunoprecipitation i.e. after precipitation with anti-EGR1 antibodies an additional precipitation round was carried out with anti-RXRA antibodies. We also controlled RXRA expression level as this factor is induced by TGF-β1, unlike EGR1 mRNA and protein (Fig. 4A). EGR1 demonstrated maximal binding to CCL2 promoter already at 1 h of TGF-β1 treatment (Fig. 5B), in agreement with existing data on direct EGR1 activation by TGF-β130. The strength of RXRA binding to CCL2 promoter also correlated with its expression level (Fig. 5B). These data indicate time-resolved binding of EGR1 and RXRA transcription factors to CCL2 promoter in response to TGF-β, suggesting largely independent action of these trascription on CCL2 gene expression. Indeed, crosslinked chromatin fragments precipitated with anti-EGR1 antibodies could not be precipitated with anti-RXRA antibodies in co-immunoprecipitation assay. The strength of combined EGR1 and RXRA binding to CCL2 promoter correlates well with TGF-β1-induced CCL2 expression and promoter activity (Fig. 2) and provides a mechanistic explanation for transcriptional activation of the CCL2 gene by these two factors for an extended period of time.
Point mutations in EGR1 and RXRA binding sites in CCL2 promoter completely abolished its activation by TGF-β
In order to verify the roles of the EGR1 and RXRA transcription factors in TGF-β-dependent regulation of the CCL2 promoter, we generated a luciferase reporter construct containing the CCL2 promoter with point mutations in the EGR1 and RXRA sites. The EGR1- and RXRA-binding sites in CCL2 promoter were overlapped, and their consensus sequences are highly similar; therefore, mutations in their key positions should damage both of them (schematically illustrated on the Fig. 6A).
Preliminary, we applied a pull-down assay32 to test the influence of these mutations on the efficiency of EGR1 and RXRA binding to the CCL2 promoter. For this reason, we generated two types of amplicons: the − 244/− 1 region of the CCL2 promoter and the same region with point mutations in the EGR1/RXRA sites (Fig. 6B). For precipitation, we used nuclear extracts from MDA-MB-231 and HCC1937 cells and anti-EGR1 or anti-RXRA antibodies. We concluded that the introduced mutations totally abrogated EGR1 and RXRA1 binding to the CCL2 promoter in both cell lines (Fig. 6B).
In the next step, we compared the activity of a full-size CCL2 promoter and its mutated variant in normal conditions and in the presence of TGF-β1 (10 ng/mL, 24 h) (Fig. 6C). Mutation of the EGR1/RXRA binding sites resulted in a full absence of the effect of TGF-β1 on CCL2 promoter activity in both the MDA-MB-231 and HCC1937 cell lines. This result agrees with both the pull-down and CHIP data and indicates the exclusive role of the EGR1/RXRA binding sites in the TGF-β-dependent regulation of the CCL2 promoter.
A direct correlation between the CCL2 and TGF-β levels is typical for progressive stages of breast cancer as was recently shown using both clinical samples and in vitro studies14. In vivo studies applying the 4T1-BALB/c BC mouse model demonstrated that the inhibition of TGF-β causes a significant reduction in the levels of CCL2 expression in the primary tumor site, which correlates with lower levels of lung metastases14. We verified these data using MDA-MB-231 and HCC1937 triple negative human breast cancer cell lines, which are reported to overexpress CCL217. These cells demonstrated a response to TGF-β1 that was detected by the induction of the expression levels of the main TGF-β targets1, IL-11 and CXCR4 (Fig. 2A), and higher levels of phospho-SMAD3 (Ser 204) and phospho-SMAD2 (Ser465/467) (Fig. 2B), which are considered as the key participant of the TGF-β intracellular cascade20. All of these TGF-β-dependent effects correlated with stimulation of the CCL2 mRNA (Fig. 2A) and protein (Fig. 2B) levels that confirm the previously published data. Thereby, TGF-β undoubtedly acts as an activator of CCL2 expression in progressive breast cancer; however, the molecular mechanism of this action remains unknown.
Using the current epigenetic data presented in the UCSC Genome Browser, we identified the region spanning from − 1196 to + 488 from the CCL2 transcription start site as a potential CCL2 promoter. TGF-β1-induced activation of MDA-MB-231 and HCC1937 breast cancer cells led to an increase in the activity of the CCL2 promoter in the luciferase reporter system (Fig. 2C), and this was fully provided by its − 244/− 1 region (Fig. 3). It should be noted that p-SMAD2/3-SMAD4 complex, which is considered as the canonical effector of intracellular signaling of TGF-β receptor acting as a transcriptional activator21,22, is not involved in direct CCL2 promoter activation since only SMAD3 knockdown but not that of SMAD2 or SMAD4 influenced the level of CCL2 promoter activity after TGF-β1 treatment (Fig. 2D,E). Bioinformatical analysis of 244/− 1 TGF-β-dependent region made it possible to predict potential binding sites for the transcription factors. The extensive list of transcription factors has been shortened as a result of literature annotation. We were interested only in the factors whose activity is described as dependent on TGF-β-signaling in cancer cells: EGR125, EGR226, PAX627, RARA and RXRA28, and SP129. Among these factors, the knock-down of only EGR1 and RXRA completely abolished the effect of CCL2 promoter activation in response to TGF-β1 (Fig. 4B). Interestingly, RARA knock-down did not have an effect on the promoter activity, indicating that RXRA probably binds CCL2 promoter as a homodimer. Additional experiments supported the role of EGR1 and RXRA in TGF-β-dependent regulation of the CCL2 promoter as their knock-down resulted in the absence of TGF-β-induced increase in CCL2 expression (Fig. 4D), both factors demonstrated binding to the promoter in a TGF-β1-dependent manner (Fig. 5), and point mutagenesis of their common binding site led to the loss of the ability of TGF-β1 to activate the CCL2 promoter (Fig. 6). Of note, EGR1 and RXRA bind to the CCL2 promoter independently but with different kinetics which may explain their essential and independent roles in TGF-β-induced CCL2 promoter activation.
The described data indicate EGR1 and RXRA as the key link between the TGF-β-induced pathways and CCL2 expression and allow us to propose a positive regulatory loop (Fig. 7). Research previously described that high CCL2 levels directly correlated with intense macrophage polarization to the M2 phenotype and secretion of CCL22, which attracts and accumulates Th2 cells14. The presence of M2 macrophages is associated with the general anti-inflammatory response33 and with production of TGF-β, which could cause further stimulation of CCL2 expression in breast cancer cells via EGR1 and RXRA. The participation of the EGR1 and RXRA transcription factors in such positive regulatory loops is in agreement with their anti-inflammatory functions. EGR1 is known to activate expression of a range of anti-inflammatory genes, including IL434,35, and is also involved in the positive regulation of TGF-β transcription36. In its turn, RXRA provides an anti-inflammatory effect by repressing transcription of IL-12 and TNF-α and induction of IL-1037. Therefore, activation of CCL2 expression could be an anti-inflammatory effect of these factors that was not previously described.
Special attention should be paid to the fact that both RXRA and EGR1 are independently essential for TGF-β-dependent activation of the CCL2 gene promoter and subsequent induction of CCL2 expression. We did not set out to reveal the precise mechanism of participative action of these factors; however, we could propose a possible model (Fig. 7) based on the existing information and on our CHIP and gene expression data (Fig. 5). EGR1 is known to be a rapid-acting transcription factor that directly binds to the activated SMAD3, translocates to the nucleus, and performs transcriptional activation of the target genes30. The specific involvement of SMAD3 via interaction with EGR1 may explain why SMAD3 knockdown specifically abrogates the TGF-β-induced activation of CCL2 promoter (Fig. 2E). Accordingly, we did not observe induction in EGR1 expression by TGF-β (Fig. 4A,C), but registered rapid changes in its binding to CCL2 promoter (Fig. 5). In addition, EGR1 is reported to act as an epigenetic modulator in different tissues38,39, including breast cancer40, which results in the ability to influence the methylation context around its binding region and significantly change the affinity of other factors to this region40.
In addition to previously described anti-inflammatory functions of EGR1, its action could also provide some features of the pro-inflammatory response, including NF-kB activation41, and is inhibited by the secondary long-lasting processes triggered by TGF-β-dependent signaling. For example, TGF-β induces LXRA, RXRA, and RARA expression levels42. These factors are known to produce the overall anti-inflammatory response37,43 and, particularly, reduce EGR1 expression levels44. These processes presumably lead to a decrease in EGR1 levels and to subsequent involvement of RXRA in the activation of the CCL2 promoter. Indeed, RXRA binding activity correlates well with its expression level (Fig. 5). In summary, rapid EGR1 action in response to TGF-β could lead to both activation of the CCL2 promoter and modification of its epigenetic context but also is inhibited itself in a short time. RXRA, on the contrary, could bind to the prepared CCL2 promoter region and provide long-lasting activation effects. Thereby, both EGR1 and RXRA could be necessary for complex activation of the CCL2 promoter in response to TGF-β.
We conclude that, in this study, we provided a possible mechanism that underlies TGF-β-dependent regulation of the CCL2 gene promoter in triple-negative advanced breast cancer cells.
Materials and methods
MDA-MB-231 and HCC1937 cell lines were maintained in a local stock of the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry RAS (Moscow, Russia) and kindly provided by Dr. D.S. Kravchenko. The stocks of MDA-MB-231 and HCC1937 cells were recently authenticated using commercially performed STR analysis (Gordiz, Moscow, Russia, data not shown). Both cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Paneco, Moscow, Russia) supplemented with 10% fetal bovine serum.
Scientific Council of the Engelhardt Institute of Molecular Biology declared no ethical approval requirements for experiments performed on the commercially available cell lines used in the study.
RNA isolation, reverse transcription, and real-time quantitative RT-PCR
The total RNA was extracted from cells using ExtractRNA reagent (Evrogen, Moscow, Russia) according to the manufacturer’s protocol. cDNA was generated using the M-MULV reverse transcriptase and oligo-dT primer from the MMLV RT kit (Evrogen, Moscow, Russia). Quantitative RT-PCR was performed using the protocol and PCR program described earlier45 and specific primers designed to amplify intron-spanning fragments of human β-actin, CCL2, CXCR4, IL11, EGR1, EGR2, PAX6, RARA, RXRA, and SP1 genes (Supplementary Table S1). The results were calculated using ΔCt method, and all expression levels of target genes were normalized to β-actin.
Western blot analysis
The protocols for the total cell lysate preparation, electrophoresis, transfer to the nitrocellulose membrane, and band visualization were described earlier15. For analysis of EGR1 and RXRA protein levels we used nuclear extracts prepared according to the previously described protocol in the same manner as for the pull-down assay32. The membranes were pre-blocked using 3% BSA and incubated with anti-pSMAD3 (Ser204) antibodies (PA5-36877, Thermo Fisher Scientific, Waltham, MA, USA) at a 1:2000 dilution, anti-CCL2 antibodies (ab9669, Abcam, Cambridge, UK) at a 1:2000 dilution, anti-pSMAD2 (Ser465/467) antibodies (138D4, Cell Signaling Technology, Danvers, MA, USA) at a 1:2000 dilution, anti-SMAD4 antibodies (D3R4N, Cell Signaling Technology, Danvers, MA, USA) at a 1:3000 dilution, anti-SMAD6 antibodies (sc-25321, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a 1:2000 dilution, anti-SMAD7 antibodies (ab216428, Abcam, Cambridge, UK) at a 1:3000 dilution, anti-EGR1 antibodies (44d5, Cell Signaling Technology, Danvers, MA, USA) at a 1:3000 dilution, anti-RXRA antibodies (d6h10, Cell Signaling Technology, Danvers, MA, USA) at a 1:3000 dilution, anti-PCNA antibodies (D3H8P, Cell Signaling Technology, Danvers, MA, USA) at a 1:3000 dilution as a loading control for nuclear extracts and anti-β-actin antibodies (ab8229, Abcam, Cambridge, UK) at a 1:3000 dilution as a loading control for whole-cell lysates. Gel images of three independent repeats were analyzed using ImageJ software to determine integral densities of the bands. The values of integral densities to β-actin for CCL2 and pSMAD3 were normalized and to PCNA for RXRA and EGR1.
Molecular cloning and luciferase reporter constructs
We amplified a potential full-size CCL2 promoter region (Prom 1) located within positions − 1196 and + 488 in response to the CCL2 transcription start site (TSS) by PCR using human genomic DNA isolated from MDA-MB-231 cells and specific primers containing HindIII и NcoI restriction sites (Supplementary Table S1). The Prom 1 region was cloned to a pGL3 base luciferase reporter vector (Promega, Madison, WI, USA). We assembled luciferase reporter plasmids containing deletion variants of CCL2 promoter: Prom 2 (− 735/+ 488), Prom 3 (− 563/+ 488), Prom 4 (− 443/+ 488), Prom 5 (− 244/+ 488), and Prom 6 (− 1/+ 488), (Schematically illustrated on the Fig. 2); and a Prom 1 variant with point mutations in the predicted EGR1 and RXRA binding sites (Schematically illustrated in Fig. 6A).
Luciferase reporter assay
MDA-MB-231 and HCC1937 cells were electroporated with 10 μg of purified plasmid DNA and 0.1 μg of pRL-CMV Renilla luciferase control reporter vector (Promega, Madison, WI, USA) using the Neon Transfection System (Thermo Fisher Scientific, Waltham, MA, USA) and the following regimens: four 10 ms 1400 V pulses for MDA-MB-231, and three 10 ms 1550 V pulses for HCC1937. Firefly luciferase activity was measured as described earlier46, and normalized to the activity of Renilla luciferase in order to account for the variations in cell transfection efficiency.
Knockdown of studied transcription factors and the proteins of SMAD family using siRNA
We used previously published siRNAs against SMAD2, SMAD347 and SMAD448 proteins and EGR1, EGR2, PAX6, RARA, RXRA, and SP1 transcription factors49. The sequences of the siRNAs are represented in Supplementary Table S1. Commercially synthesized single-stranded RNAs (Syntol, Moscow, Russia) were annealed as previously described50. MDA-MB-231 and HCC1937 cells were transfected with siRNA duplexes (500 pmol of per 5 million cells) 48 h before transfection with the luciferase constructs and a further 200 pmol to extend the silencing effect.
Chromatin immunoprecipitation (ChIP) assay
We applied the cross-linking chromatin immunoprecipitation (X-ChIP) protocol as described earlier51. Briefly, after the lysis of 2 × 107 of MDA-MB-231 or HCC1937 cells containing protein-DNA complexes preliminary cross-linked with 0.75% formaldehyde, these complexes were sonicated to obtain average DNA fragment sizes of 700 bp, incubated with antibodies to RXRA (d6h10, Cell Signaling Technology, Danvers, MA, USA) or EGR1 (44d5, Cell Signaling Technology, Danvers, MA, USA), and precipitated with pre-blocked protein A sepharose beads. After the elution of protein-DNA complexes and DNA purification, the target DNA was quantified by real-time PCR. We used four types of controls: a background control without lysate; a nonspecific precipitation control without antibodies; a control with isotype rabbit IgG antibodies (DA1E, Cell Signaling Technology, Danvers, MA, USA); and an amplicon from a nonspecific locus containing no predicted RXRA- or EGR1-binding sites. The primer sequences are represented in Supplementary Table S1. None of the control precipitations produced signals above the background level.
We performed a pull-down assay according to our previously published original protocol32. Briefly, we amplified a 245-bp fragment of CCL2 promoter (− 244/− 1) and the same fragment with point mutations in EGR1/RXRA binding sites (Fig. 6B). An amplicon from a non-specific locus of the same length that did not contain any predicted EGR1/RXRA binding sites served as a negative control. The primer sequences are represented in Supplementary Table S1. The protocols of the isolation of nuclear extracts from MDA-MB-231 and HCC1937 cell lines, the immunoprecipitation of protein-DNA complexes, and quantification of bound DNA probes by real-time PCR were described earlier32. For precipitation, we used anti-RXRA (d6h10, Cell Signaling Technology, Danvers, MA, USA) and anti-EGR1 (44d5, Cell Signaling Technology, Danvers, MA, USA) antibodies. We used the following controls to calculate the background signal level: with an amplicon from a nonspecific locus; without nuclear extract; without antibodies; and isotype control with rabbit IgG (DA1E, Cell Signaling Technology, Danvers, MA, USA).
We used Microsoft Excel and Graphpad Prism software for our statistical analyses. Statistical significance was determined using a two-tailed unpaired Student’s t-test. The data are represented as the mean ± SD.
C–C motif ligand 2
C-X-C chemokine receptor type 4
Early growth response protein 1
Early growth response protein 2
- MMLV RT:
Moloney murine leukemia virus reverse transcriptase
Moloney murine leukemia virus
Paired box protein 6
Proliferating cell nuclear antigen
Retinoic acid receptor alpha
Retinoid X receptor alpha
Standard error of the mean
Small interfering RNA
Mothers against decapentaplegic homolog 3
Specificity protein 1
- STR analysis:
Short tandem repeat analysis
Zarzynska, J. M. Two faces of TGF-Beta1 in breast cancer. Mediat. Inflamm. 2014, 141747 (2014).
Barcellos-Hoff, M. H. & Akhurst, R. J. Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Res. 11, 202 (2009).
Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer 13, 788–799 (2013).
Wang, Y. & Zhou, B. P. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin. J. Cancer 30, 603–611 (2011).
Bierie, B. et al. Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Investig. 119, 1571–1582 (2009).
Acharyya, S. et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165–178 (2012).
Hsu, Y.-L., Hou, M.-F., Kuo, P.-L., Huang, Y.-F. & Tsai, E.-M. Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/Snail signaling pathway. Oncogene 32, 4436–4447 (2013).
Osuala, K. O. & Sloane, B. F. Many roles of CCL20: Emphasis on breast cancer. Postdoc J. 2, 7–16 (2014).
Zhang, F. et al. Transforming growth factor-β promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J. Biol. Chem. 284, 17564–17574 (2009).
Kitamura, T. et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 212, 1043–1059 (2015).
Chen, X. et al. CCL2/CCR2 regulates the tumor microenvironment in HER-2/neu-driven mammary carcinomas in mice. PLoS ONE 11, e0165595 (2016).
Williams, C. B., Yeh, E. S. & Soloff, A. C. Tumor-associated macrophages: Unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer 2, 15025 (2016).
Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N. & Muschel, R. J. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7, 28697–28710 (2016).
Mandal, P. K. et al. CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-β-induced breast cancer progression. Immunobiology 223, 151–161 (2018).
Mitkin, N. A. et al. Protective C allele of the single-nucleotide polymorphism rs1335532 is associated with strong binding of Ascl2 transcription factor and elevated CD58 expression in B-cells. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 3211–3220 (2018).
Hoffman, M. M. et al. Unsupervised pattern discovery in human chromatin structure through genomic segmentation. Nat. Methods 9, 473–476 (2012).
Dutta, P., Sarkissyan, M., Paico, K., Wu, Y. & Vadgama, J. V. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis. Breast Cancer Res. Treat. 170, 477–486 (2018).
Bai, F. et al. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. Cancer Res. 74, 6161–6172 (2014).
Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515–527 (2006).
Wang, G., Matsuura, I., He, D. & Liu, F. Transforming growth factor-β-inducible phosphorylation of Smad3. J. Biol. Chem. 284, 9663–9673 (2009).
Albers, R. E., Selesniemi, K., Natale, D. R. C. & Brown, T. L. TGF-β induces Smad2 phosphorylation, are induction, and trophoblast differentiation. Int. J. Stem Cells 11, 111–120 (2018).
Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577–584 (2003).
Zhang, J. et al. The regulation of TGF-β/SMAD signaling by protein deubiquitination. Protein Cell 5, 503–517 (2014).
Kulakovskiy, I. V. et al. HOCOMOCO: Towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis. Nucleic Acids Res. 46, D252–D259 (2018).
Chen, S.-J. et al. The early-immediate gene EGR-1 is induced by transforming growth factor-β and mediates stimulation of collagen gene expression. J. Biol. Chem. 281, 21183–21197 (2006).
Gregory, K. J., Morin, S. M. & Schneider, S. S. Regulation of early growth response 2 expression by secreted frizzled related protein 1. BMC Cancer 17, 473 (2017).
Qian, Z. et al. Investigating the mechanism by which SMAD3 induces PAX6 transcription to promote the development of non-small cell lung cancer. Respir. Res. 19, 262 (2018).
Pendaries, V., Verrecchia, F., Michel, S. & Mauviel, A. Retinoic acid receptors interfere with the TGF-β/Smad signaling pathway in a ligand-specific manner. Oncogene 22, 8212–8220 (2003).
Zhao, Y. et al. TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. Mol. Oncol. 12, 305–321 (2018).
Fortin, J. & Bernard, D. J. SMAD3 and EGR1 physically and functionally interact in promoter-specific fashion. Cell. Signal. 22, 936–943 (2010).
Jungert, K. et al. Sp1 is required for transforming growth factor-β-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer Res. 67, 1563–1570 (2007).
Mitkin, N. A., Korneev, K. V., Gorbacheva, A. M. & Kuprash, D. V. Relative efficiency of transcription factor binding to allelic variants of regulatory regions of human genes in immunoprecipitation and real-time PCR. Mol. Biol. 53, 346–353 (2019).
Najafi, M. et al. Macrophage polarity in cancer: A review. J. Cell. Biochem. 120, 2756–2765 (2019).
Lohoff, M. et al. Early growth response protein-1 (Egr-1) is preferentially expressed in T helper type 2 (Th2) cells and is involved in acute transcription of the Th2 cytokine interleukin-4. J. Biol. Chem. 285, 1643–1652 (2010).
Veremeyko, T., Yung, A. W. Y., Anthony, D. C., Strekalova, T. & Ponomarev, E. D. Early growth response gene-2 is essential for M1 and M2 macrophage activation and plasticity by modulation of the transcription factor CEBPβ. Front. Immunol. 9, 2515 (2018).
Baron, V., Adamson, E. D., Calogero, A., Ragona, G. & Mercola, D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin. Cancer Gene Ther. 13, 115–124 (2006).
Yamamoto, A., Kakuta, H., Miyachi, H. & Sugimoto, Y. Involvement of the retinoid X receptor ligand in the anti-inflammatory effect induced by peroxisome proliferator-activated receptor. PPAR Res. 2011, 840194 (2011).
Sun, Z. et al. EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity. Nat. Commun. 10, 3892 (2019).
Spaapen, F. et al. The immediate early gene product EGR1 and polycomb group proteins interact in epigenetic programming during chondrogenesis. PLoS ONE 8, e58083 (2013).
Zhou, X., Chen, Z. & Cai, X. Identification of epigenetic modulators in human breast cancer by integrated analysis of DNA methylation and RNA-Seq data. Epigenetics 13, 473–489 (2018).
Shajahan-Haq, A. N. et al. EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. Oncotarget 8, 96865–96884 (2017).
Chen, Y., Takeshita, A., Ozaki, K., Kitano, S. & Hanazawa, S. Transcriptional regulation by transforming growth factor β of the expression of retinoic acid and retinoid X receptor genes in osteoblastic cells is mediated through AP-1. J. Biol. Chem. 271, 31602–31606 (1996).
Xu, Q. & Kopp, J. B. Retinoid and TGF-β families: Crosstalk in development, neoplasia, immunity, and tissue repair. Semin. Nephrol. 32, 287–294 (2012).
Guillem-Llobat, P. & Íñiguez, M. A. Inhibition of lipopolysaccharide-induced gene expression by liver X receptor ligands in macrophages involves interference with early growth response factor 1. Prostagland. Leukot. Essent. Fat. Acids 96, 37–49 (2015).
Mitkin, N. A., Muratova, A. M., Schwartz, A. M. & Kuprash, D. V. The A allele of the single-nucleotide polymorphism rs630923 creates a binding site for MEF2C resulting in reduced cxcr5 promoter activity in B-cell lymphoblastic cell lines. Front. Immunol. 7, 515 (2016).
Gorbacheva, A., Korneev, K., Kuprash, D. & Mitkin, N. The risk G allele of the single-nucleotide polymorphism rs928413 creates a CREB1-binding site that activates IL33 promoter in lung epithelial cells. Int. J. Mol. Sci. 19, 2911 (2018).
Phanish, M. K., Wahab, N. A., Colville-Nash, P., Hendry, B. M. & Dockrell, M. E. C. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem. J. 393, 601–607 (2006).
Morishita, Y. et al. siRNAs targeted to Smad4 prevent renal fibrosis in vivo. Sci. Rep. 4, 6424 (2014).
Hasson, S. A. et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature 504, 291 (2013).
Mitkin, N. A. et al. p63 and p73 repress CXCR5 chemokine receptor gene expression in p53-deficient MCF-7 breast cancer cells during genotoxic stress. Biochim. Biophys. Acta Gene Regul. Mech. 1860, 1169–1178 (2017).
Mitkin, N. A. et al. P53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells. Sci. Rep. https://doi.org/10.1038/srep09330 (2015).
Most of the promoter analysis (Figs. 1, 4) was supported by Grant 18-54-45020 from Russian Foundation for Basic Research. Gene expression studies (Fig. 2) were supported by Grant 19-74-00096 from Russian Science Foundation. Deletion screening studies (Fig. 3) were supported by Grant 19-14-00341 from Russian Science Foundation. Chromatin immunoprecipitation studies and point mutagenesis (Figs. 5, 6, 7) were supported by Grant 075-15-2019-1660 from the Ministry of Science and Higher Education of the Russian Federation.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gorbacheva, A.M., Uvarova, A.N., Ustiugova, A.S. et al. EGR1 and RXRA transcription factors link TGF-β pathway and CCL2 expression in triple negative breast cancer cells. Sci Rep 11, 14120 (2021). https://doi.org/10.1038/s41598-021-93561-6
This article is cited by
Cellular & Molecular Immunology (2023)
Tumor-mesothelium HOXA11-PDGF BB/TGF β1-miR-181a-5p-Egr1 feedforward amplifier circuity propels mesothelial fibrosis and peritoneal metastasis of gastric cancer
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
npj Precision Oncology (2023)